Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096234 · ClinicalTrials.gov registry record · Phase 1
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05096234: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT05096234 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096234, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Primary Outcome
Spearman correlation between changes in SUV in \[18F\]F-AraG signal on PET imaging to changes in T-cell infiltrates in biopsy samples
Interventions
- DRUG [ 18F]F-AraG PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2023-10-09 |
| Phase | Phase 1 |
Why NCT05096234 stopped before completion
NCT05096234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which [ 18F]F-AraG PET is the first listed.
NCT05096234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05096234 about?
NCT05096234 is a clinical study titled "18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma". This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
What is the current status of trial NCT05096234?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-09-28. Estimated completion is 2023-10-09.
What interventions are being tested in trial NCT05096234?
The interventions under investigation include: [ 18F]F-AraG PET (DRUG).
Who is sponsoring clinical trial NCT05096234?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05096234's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI